Abstract
Tumor necrosis factor α (TNFα) is a crucial mediator involved in the communications between immune and nervous systems in physiological conditions, and its relevance is amplified during disease. Considered originally detrimental and a target for therapeutic intervention, recently it has also gained attention for its protective role, especially in central nervous system (CNS) confined diseases. Thus, TNFα has become the key molecule illustrating the peculiar and still not completely understood pathways by which inflammatory and immune reactions occur in the brain. Several human pathologies that lack an efficient therapy and that carry enormous social costs rely on these mechanisms. Thus, further research is needed to improve our knowledge and to allow the identification of therapeutic targets or strategies for immune-mediated inflammatory disease of the CNS in which TNFα is primarily involved. We describe here how to induce experimental autoimmune encephalomyelitis, cerebral malaria, and brain ischemia in rodents, and some protocols to analyze them. The application of innovative research strategies or original therapeutic approaches to these experimental models may be rewarding in terms of advancement in a field that is crucial for the management of many human patients.
Key Words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Breder, C. D., Tsujimoto, M., Terano, Y., Scott, D. W., and Saper, C. B. (1993) Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J. Comp. Neurol. 337, 543–567.
Lieberman, A. P., Pitha, P. M., Shin, H. S., and Shin, M. L. (1989) Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl. Acad. Sci. USA 86, 6348–6352.
Frei, K., Siepl, C., Groscurth, P., Bodmer, S., Schwerdel, C., and Fontana, A. (1987) Antigen presentation and tumor cytotoxicity by interferon-gamma-treated microglial cells. Eur. J. Immunol. 17, 1271–1278.
Beattie, E. C., Stellwagen, D., Morishita, W., Bresnahan, J. C., Ha, B. K., Von Zastrow, M., et al. (2002) Control of synaptic strength by glial TNFalpha. Science 295, 2282–2285.
Gutierrez, E. G., Banks, W. A., and Kastin, A. J. (1993) Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 47, 169–176.
Akassoglou, K., Bauer, J., Kassiotis, G., Pasparakis, M., Lassmann, H., Kollias, G., et al. (1998) Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am. J. Pathol. 153, 801–813.
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., and Ting, J. P. (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4, 1116–1122.
Leon, L. R. (2002) Invited review: cytokine regulation of fever: studies using gene knockout mice. J. Appl. Physiol. 92, 2648–2655.
Deboer, T., Fontana, A., and Tobler, I. (2002) Tumor necrosis factor (TNF) ligand and TNF receptor deficiency affects sleep and the sleep EEG. J. Neurophysiol. 88, 839–846.
Ek, M., Engblom, D., Saha, S., Blomqvist, A., Jakobsson, P. J., and Ericsson-Dahlstrand, A. (2001) Inflammatory response: pathway across the blood-brain barrier. Nature 410, 430–431.
Selmaj, K. W., Farooq, M., Norton, W. T., Raine, C. S., and Brosnan, C. F. (1990) Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immunol. 144, 129–135.
Merrill, J. E. (1991) Effects of interleukin-1 and tumor necrosis factor-alpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev. Neurosci. 13, 130–137.
Merrill, J. E., Ignarro, L. J., Sherman, M. P., Melinek, J., and Lane, T. E. (1993) Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151, 2132–2141.
Sedgwick, J. D., Riminton, D. S., Cyster, J. G., and Korner, H. (2000) Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol. Today 21, 110–113.
Selmaj, K. W. and Raine, C. S. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23, 339–346.
Murphy, C. A., Hoek, R. M., Wiekowski, M. T., Lira, S. A., and Sedgwick, J. D. (2002) Interactions between hemopoietically derived TNFα and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain. J. Immunol. 169, 7054–7062.
Sawada, M., Kondo, N., Suzumura, A., and Marunouchi, T. (1989) Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 491, 394–397.
Osburg, B., Peiser, C., Domling, D., Schomburg, L., Ko, Y. T., Voigt, K., et al. (2002) Effect of endotoxin on expression of TNF receptors and transport of TNFalpha at the blood-brain barrier of the rat. Am. J. Physiol. Endocrinol. Metab. 283, E899–E908.
Omari, K. M. and Dorovini-Zis, K. (2003) CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium. J. Neuroimmunol. 134, 166–178.
Martino, G. and Hartung, H. P. (1999) Immunopathogenesis of multiple sclerosis: the role of T cells. Curr. Opin. Neurol. 12, 309–321.
Kieseier, B. C., Storch, M. K., Archelos, J. J., Martino, G., and Hartung, H. P. (1999) Effector pathways in immune mediated central nervous system demyelination. Curr. Opin. Neurol. 12, 323–336.
Swanborg, R. H. (2001) Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol. Rev. 184, 129–135.
Brok, H. P., Bauer, J., Jonker, M., Blezer, E., Amor, S., Bontrop, R. E., et al. (2001) Non-human primate models of multiple sclerosis. Immunol. Rev. 183, 173–185.
Uccelli, A. Animal models of demyelination of the central nervous system. In From Basic Immunology to Immune-Mediated Demyelination (Martino, G. and Adorini, L., eds.). Springer-Verlag, Milan, Italy, 1999, pp. 233–245.
Lassmann, H. (2002) Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin. Neurol. Neurosurg. 104, 168–171.
Hofman, F. M., Hinton, D. R., Johnson, K., and Merrill, J. E. (1991) Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170, 607–612.
Selmaj, K., Raine, C. S., Cannella, B., and Brosnan, C. F. (1991) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87, 949–954.
Issazadeh, S., Ljungdahl, A., Hojeberg, B., Mustafa, M., and Olsson, T. (1995) Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J. Neuroimmunol. 61, 205–212.
Furlan, R., Martino, G., Galbiati, F., Poliani, P. L., Smiroldo, S., Bergami, A., et al. (1999) Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 163, 2403–2409.
Renno, T., Krakowski, M., Piccirillo, C., Lin, J. Y., and Owens, T. (1995) TNFalpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. J. Immunol. 154, 944–953.
Probert, L., Eugster, H. P., Akassoglou, K., Bauer, J., Frei, K., Lassmann, H., et al. (2000) TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 123, 2005–2019.
Ruuls, S. R., Hoek, R. M., Ngo, V. N., McNeil, T., Lucian, L. A., Janatpour, M. J., et al. (2001) Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15, 533–543.
Eugster, H. P., Frei, K., Bachmann, R., Bluethmann, H., Lassmann, H., and Fontana, A. (1999) Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur. J. Immunol. 29, 626–632.
Liu, J., Marino, M. W., Wong, G., Grail, D., Dunn, A., Bettadapura, J., et al. (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4, 78–83.
Ruddle, N. H., Bergman, C. M., McGrath, K. M., Lingenheld, E. G., Grunnet, M. L., Padula, S. J., et al. (1990) An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172, 1193–1200.
Selmaj, K., Raine, C. S., and Cross, A. H. (1991) Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30, 694–700.
Croxford, J. L., Triantaphyllopoulos, K. A., Neve, R. M., Feldmann, M., Chernajovsky, Y., and Baker, D. (2000) Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J. Immunol. 164, 2776–2781.
The Lenercept Group. (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53, 457–465.
van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., von Blomberg, B. M., et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47, 1531–1534.
Luhan, M. Malaria. WHO Press Office Fact Sheet 94. World Health Organization, Geneva, Switzerland, 1996, pp. 1–3.
Najera, J. A. and Hempel, J. The Burden of Malaria. WHO Press Office Publication CTD/MAL/96.10, World Health Organization, Geneva, Switzerland, 1996, pp. 1–58.
Sachs, J. and Malanay, P. (2002) The economic and social burden of malaria. Nature 415, 680–685.
Greenwood, B. M., Bradley, A. K., Greenwood, A. M., Byass, P., Jammeh, K., Marsh, K., et al. (1987) Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans. R. Soc. Trop. Med. Hyg. 81, 478–486.
Clark, I. A., Chaudhri, G., and Cowden, W. B. (1989) Roles of tumor necrosis factor in the illness and pathology of malaria. Trans. R. Soc. Trop. Med. Hyg. 83, 436–440.
Miller, L. H., Baruch, D. I., Marsh, K., and Doumbo, O. K. (2002) The pathogenic basis of malaria. Nature 415, 673–679.
Grau, G. E., Taylor, T. E., Molyneux, M. E., Wirima, J. J., Vassalli, P., Hommel, M., et al. (1989) Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. 320, 1586–1591.
Kwiatkowski, D., Hill, A. V. S., Sambou, I., Twumasi, P., Castracane, J., Manogue, K. R., et al. (1990) TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 336, 1201–1204.
Butcher, G. A., Garland, T., Ajdukiewicz, A. B., and Clark, I. A. (1990) Serum tumor necrosis factor associated with malaria in patients in the Solomon Islands. Trans. R. Soc. Trop. Med. Hyg. 84, 658–661.
Shaffer, N., Grau, G. E., Hedberg, K., Davachi, F., Lyamba, B., Hightower, A. W., et al. (1991) Tumor necrosis factor and severe malaria. J. Infect. Dis. 163, 96–101.
Di Perri, G., Di Perri, I. G., Monteiro, G. B., Bonora, S., Hennig, C., Cassatella, M., et al. (1995) Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J. Infect. Dis. 171, 1317–1322.
Manish, R., Tripathy, R., and Das, B.K. (2003) Plasma glucose and tumor necrosis factor-alpha in adult patients with severe falciparum malaria. Trop. Med. Int. Health 8, 125–128.
Sinha, B., Semmler, J., Eisenhut, T., Eigler, A., and Endres, S. (1995) Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25, 147–153.
Lou, J., Lucas, R., and Grau, G. E. (2002) Pathogenesis of cerebral malaria: recent experimental data and possible applications in humans. Clin. Microbiol. Rev. 14, 810–820.
Grau, G. E., Piguet, P. F., Vassalli, P., and Lambert, P. H. (1989) Tumor-necrosis factor and other cytokines in cerebral malaria: experimental and clinical data. Immunol. Rev. 112, 49–70.
Finley, R. W., Mackey, L. J., and Lambert, P. H. (1982) Virulent P. berghei malaria: prolonged survival and decreased cerebral pathology in T cell-deficient nude mice. J. Immunol. 129, 2213–2218.
Grau, G. E., Piguet, P. F., Engers, H. D., Louis, J. A., Vassalli, P., and Lambert, P. H. (1986) L3T4+ T lymphocytes play a major role in the pathogensis of murine cerebral malaria. J. Immunol. 137, 2348–2354.
Belnoue, E., Kayibanda, M., Vigario, A. M., Deschemin, J.C., van Rooijen, N., Viguier, M., et al. (2002) On the pathogenic role of brain-sequestered αβCD8+ T cells in experimental cerebral malaria. J. Immunol. 169, 6369–6375.
Grau, G. E., Gretener, D., and Lambert, P. H. (1987) Prevention of murine cerebral malaria by low dose cyclosporin A. Immunology 61, 521–525.
Senaldi, G., Shaklee, C. L., Guo, J., Martin, L., Boone, T., Mak, T. W., et al. (1999) Protection against the mortality associated with disease models mediated by TNF and IFN-gamma in mice lacking IFN regulatory factor-1. J. Immunol. 163, 6820–6826.
Grau, G. E., Fajardo, L. F., Piguet, P. F., Allet, B., Lambert, P. H., and Vassalli, P. (1986) Tumor necrosis factor/cachectin as an essential mediator in murine cerebral malaria. Science 237, 1210–1212.
Beutler, B., Milsark, I. W., and Cerami, A. (1986) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 229, 869–871.
Garcia, I., Araki, K., Miyazaki, Y., Araki, M., Juillard, P., Grau, G. E., et al. (1995) Transgenic mice expressing soluble TNFR1-IgG3 molecules are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur. J. Immunol. 25, 2401–2407.
Lucas, R., Lou, J. N., Juillard, P., Moore, M., Bluethmann, H., and Grau, G. E. (1997) Respective role of TNF receptors in the development of experimental cerebral malaria. J. Neuroimmunol. 72, 143–148.
Grau, G. E., Pointaire, P., Piguet, P. F., Engers, H. D., Louis, J. A., Vassalli, P., et al. (1991) Late administration of monoclonal antibody to leukocyte function antigen 1 abrogates incipient murine cerebral malaria. Eur. J. Immunol. 21, 2265–2267.
Dirnagl, U., Iadecola, C., and Moskowitz, M. A. (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391–397.
Lee, J. M., Grabb, M. C., Zipfel, G. J., and Choi, D. W. (2000) Brain tissue responses to ischemia. J. Clin. Invest. 106, 723–731.
Liu, T., Clark, R. K., McDonnell, P. C., Young, P. R., White, R. F., Barone F. C., et al. (1994) Tumor necrosis factor-expression in ischemic neurons. Stroke 25, 1481–1488.
Buttini, M., Appel, K., Sauter, A., Gebicke-Haerter, P.-J., and Boddeke, H. W. (1996) Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience 71, 1–16.
Botchkina, G. I., Meistrell, M. E., III, Botchkina, I. L., and Tracey, K. J. (1997) Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol. Med. 3, 765–781.
Sairanen, T., Carpen, O., Karjalainen-Lindsberg, M. L., Paetau, A., Turpeinen, U., Kaste, M., et al. (2001) Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. Stroke 32, 1750–1758.
Meistrell, M. E., III, Botchkina, G. I., Wang, H., Di Santo, E., Cockroft, K. M., Bloom, O., et al. (1997) Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock 8, 341–348.
Dawson, D. A., Martin, D., and Hallenbeck, J. M. (1996) Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci. Lett. 218, 41–44.
Navashiro, H., Martin, D., and Hallenbeck, J. M. (1997) Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J. Cereb. Blood Flow Metab. 17, 229–232.
Nawashiro, H., Martin, D., and Hallenbeck, J. M. (1997) Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res. 778, 265–271.
Brett, J., Gerlach, H., Nawroth, P., Steinberg, S., Godman, G., and Stern, D. (1989) Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J. Exp. Med. 169, 1977–1991.
Tureen, J. (1995) Effect of recombinant human tumor necrosis factor-alpha on cerebral oxygen uptake, cerebrospinal fluid lactate, and cerebral blood flow in the rabbit: role of nitric oxide. J. Clin. Invest. 95, 1086–1091.
Decoster, E., Vanhaesebroeck, B., Vandenabeele, P., Grooten, J., and Fiers, W. (1995) Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J. Biol. Chem. 270, 18,473–18,478.
Wong, G. H. and Goeddel, D. V. (1994) Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J. Immunol. 152, 1751–1755.
Relton, J. K. and Rothwell, N. J. (1992) Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. 29, 243–246.
Zhang, J., Dawson, V. L., Dawson, T. M., and Snyder, S. H. (1994) Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263, 687–689.
Wang, X., Yue, T. L., Barone, F. C., and Feuerstein, G. Z. (1995) Demonstration of increased endothelial-leukocyte adhesion molecule-1 mRNA expression in rat ischemic cortex. Stroke 26, 1665–1669.
Bruce, A. J., Boling, W., Kindy, M. S., Peschon, J., Kraemer, P. J., Carpenter, M. K., et al. (1996) Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 2, 788–794.
Shohami, E., Ginis, I., and Hallenbeck J. M. (1999) Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 10, 119–130.
Ginsberg, M. D. and Busto, R. (1989) Rodent models of cerebral ischemia. Stroke 20, 1627–1642.
Luvisotto, T. L. and Sutherland, G. R. Animal models of stroke. In Advances in Neurochemistry (Bachelard, H., ed.), Plenum, New York, 1997, pp. 117–144.
Chen, S. T., Hsu, C. Y., Hogan, E. L., Maricq, H., and Balentine, J. D. (1986) A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke 17, 738–743.
Bederson, J. B., Pitts, L. H., Germano, S. M., Nishimura, M. C., Davis, R. L., and Bartkowski, H. M. (1986) Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17, 1304–1308.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Furlan, R., Villa, P., Senaldi, G., Martino, G. (2004). TNFα in Experimental Diseases of the CNS. In: Corti, A., Ghezzi, P. (eds) Tumor Necrosis Factor. Methods in Molecular Medicine™, vol 98. Humana Press. https://doi.org/10.1385/1-59259-771-8:171
Download citation
DOI: https://doi.org/10.1385/1-59259-771-8:171
Publisher Name: Humana Press
Print ISBN: 978-1-58829-223-0
Online ISBN: 978-1-59259-771-0
eBook Packages: Springer Protocols